Kura Oncology KURA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $39.08M-73.8% | $149.1M+56.5% | $95.29M+16.3% | $81.95M+59.8% | $51.27M-77.2% | ||
| $541.74M+4.6% | $518.14M+14.0% | $454.38M-17.2% | $548.78M-9.6% | $606.92M+20.7% | ||
| $9.35M+6.2% | $8.8M-75.5% | $35.94M+686% | $4.57M-90.6% | $48.75M+2,266% | ||
| $1.46M+102% | $722.75K+133% | $309.75K+50.0% | $206.5K+100% | $103.25K— | ||
| $623.78M-12.0% | $708.66M+14.2% | $620.66M-6.0% | $660.08M-8.9% | $724.2M-2.8% | ||
| $7.61M-3.1% | $7.86M+6.2% | $7.4M+89.1% | $3.91M+66.6% | $2.35M+39.6% | ||
| $652.55M-11.6% | $738.36M+13.7% | $649.38M-4.8% | $682.43M-8.2% | $743.76M-2.2% | ||
| $7.04M+40.4% | $5.02M-92.5% | $66.79M+26.2% | $52.93M+17.4% | $45.09M+2,970% | ||
| $47.7M-2.6% | $48.98M+0.5% | $48.75M— | —— | —— | ||
| —— | $0-100% | $4.34M+39.4% | $3.11M+62.0% | $1.92M— | ||
| $101.5M-13.2% | $116.97M-3.6% | $121.3M+13.2% | $107.17M+19.4% | $89.77M+14.0% | ||
| $9.75M+0.4% | $9.71M+82.0% | $5.34M-18.0% | $6.51M-14.9% | $7.65M+10.6% | ||
| $544.67M-3.5% | $564.23M+38.7% | $406.84M+7.9% | $376.94M-0.6% | $379.36M+9.5% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K+12.5% | $8K0.0% | ||
| -$1.25B-6.2% | -$1.17B-7.4% | -$1.09B-7.3% | -$1.02B-6.9% | -$952.85M-6.4% | ||
| $107.88M-38.0% | $174.14M-28.2% | $242.54M-20.6% | $305.49M-16.2% | $364.41M-11.9% | ||
| $652.55M-11.6% | $738.36M+13.7% | $649.38M-4.8% | $682.43M-8.2% | $743.76M-2.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kura Oncology's total assets?
- Kura Oncology (KURA) holds $652.6M in total assets, down 12.3% year over year.
- How much debt does Kura Oncology have?
- Kura Oncology carries $24.3M in total debt against $107.9M of shareholders' equity, a debt-to-equity ratio of 0.23.
- How much cash does Kura Oncology have?
- Kura Oncology holds $39.1M in cash and equivalents.
- Can Kura Oncology cover its short-term obligations?
- Its current ratio is 6.15 — current assets exceed current liabilities.
- Where does Kura Oncology's balance sheet data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
